The CRF₁ receptor antagonist, NBI-35965, abolished the activation of locus coeruleus neurons induced by colorectal distension and intracisternal CRF in ratsKOSOYAN, Hovsep P; GRIGORIADIS, Dimitri E; TACHE, Yvette et al.Brain research. 2005, Vol 1056, Num 1, pp 85-96, issn 0006-8993, 12 p.Article

NBI 30775 (R121919), an orally active antagonist of the corticotropin-releasing factor (CRF) type-1 receptor for the treatment of anxiety and depressionCHEN CHEN; GRIGORIADIS, Dimitri E.Drug development research. 2005, Vol 65, Num 4, pp 216-226, issn 0272-4391, 11 p.Article

Role of corticotropin-releasing factor receptors type 1 and 2 in modulating the rat adrenocorticotropin response to stressorsRIVIER, Catherine L; GRIGORIADIS, Dimitri E; RIVIER, Jean E et al.Endocrinology (Philadelphia). 2003, Vol 144, Num 6, pp 2396-2403, issn 0013-7227, 8 p.Article

Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonistsWILCOXEN, Keith; HUANG, Charles Q; MCCARTHY, James R et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 19, pp 3367-3370, issn 0960-894X, 4 p.Article

Corticotropin-releasing hormone (CRH) downregulates the function of its receptor (CRF₁) and induces CRF₁ expression in hippocampal and cortical regions of the immature rat brainBRUNSON, Kristen L; GRIGORIADIS, Dimitri E; LORANG, Marge T et al.Experimental neurology (Print). 2002, Vol 176, Num 1, pp 75-86, issn 0014-4886, 12 p.Article

CRF receptor type 1 and 2 expression and anatomical distribution in the rat colonCHATZAKI, Ekaterini; CROWE, Paul D; LIXIN WANG et al.Journal of neurochemistry. 2004, Vol 90, Num 2, pp 309-316, issn 0022-3042, 8 p.Article

Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, g-protein-coupling sensitivity and determinants of CRF₂ receptor selectivityHOARE, Sam R. J; SULLIVAN, Susan K; JUN FAN et al.Peptides (New York, NY. 1980). 2005, Vol 26, Num 3, pp 457-470, issn 0196-9781, 14 p.Article

Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF₁ receptor antagonistsHUANG, Charles Q; WILCOXEN, Keith M; GRIGORIADIS, Dimitri E et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 15, pp 3943-3947, issn 0960-894X, 5 p.Article

1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: Novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF₁) receptor antagonist activitiesCHEN CHEN; DAGNINO, Raymond JR; HUANG, Charles Q et al.Bioorganic & medicinal chemistry letters (Print). 2001, Vol 11, Num 24, pp 3165-3168, issn 0960-894XArticle

Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonistHEINRICHS, Stephen C; DE SOUZA, Errol B; SCHULTEIS, Gery et al.Neuropsychopharmacology (New York, NY). 2002, Vol 27, Num 2, pp 194-202, issn 0893-133XArticle

Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor₁ (CRF₁) receptor antagonistsHUANG, Charles Q; GRIGORIADIS, Dimitri E; ZHENGYU LIU et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 9, pp 2083-2086, issn 0960-894X, 4 p.Article

Drugability of Extracellular Targets : Discovery of Small Molecule Drugs Targeting Allosteric, Functional, and Subunit-Selective Sites on GPCRs and Ion ChannelsGRIGORIADIS, Dimitri E; HOARE, Samuel R. J; LECHNER, Sandra M et al.Neuropsychopharmacology (New York, NY). 2009, Vol 34, Num 1, pp 106-125, issn 0893-133X, 20 p.Article

Conformational states of the corticotropin releasing factor 1 (CRF₁) receptor: detection, and pharmacological evaluation by peptide ligandsHOARE, Sam R. J; SULLIVAN, Susan K; PAHUJA, Anil et al.Peptides (New York, NY. 1980). 2003, Vol 24, Num 12, pp 1881-1897, issn 0196-9781, 17 p.Article

Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a] pyrimidine (NBI 30775/r121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonistsCHEN CHEN; WILCOXEN, Keith M; BOZIGIAN, Haig et al.Journal of medicinal chemistry (Print). 2004, Vol 47, Num 19, pp 4787-4798, issn 0022-2623, 12 p.Article

Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubilityCHEN CHEN; WILCOXEN, Keith M; HUANG, Charles Q et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 14, pp 3669-3673, issn 0960-894X, 5 p.Article

Synthesis and SAR of 8-arylquinolines as potent corticotropin-releasing factors (CRF₁) receptor antagonistsHUANG, Charles Q; WILCOXEN, Keith; MCCARTHY, James R et al.Bioorganic & medicinal chemistry letters (Print). 2003, Vol 13, Num 19, pp 3375-3379, issn 0960-894X, 5 p.Article

Rational design, synthesis, and structure-activity relationships of aryltriazoles as novel corticotropin-releasing factor-1 receptor antagonistsLOWE, Richard F; NELSON, Jodene; SZABO, Thomas et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 5, pp 1540-1549, issn 0022-2623, 10 p.Article

Differential profile of CRF receptor distribution in the rat stomach and duodenum assessed by newly developed CRF receptor antibodiesCHATZAKI, Ekaterini; MURPHY, Brian J; LIXIN WANG et al.Journal of neurochemistry. 2004, Vol 88, Num 1, pp 1-11, issn 0022-3042, 11 p.Article

Developing novel Treatments for Mood disorders: Accelerating discoveryTAMMINGA, Carol A; NEMEROFF, Charles B; INNIS, Robert B et al.Biological psychiatry (1969). 2002, Vol 52, Num 6, pp 589-609, issn 0006-3223, 21 p.Article

Synthesis of benzoylpyrimidines as antagonists of the corticotropin-releasing factor-1 receptorWEBB, Thomas R; MORAN, Terry; HUANG, Charles Q et al.Bioorganic & medicinal chemistry letters (Print). 2004, Vol 14, Num 15, pp 3869-3873, issn 0960-894X, 5 p.Article

High-affinity CRF₁ receptor antagonist NBI-34041 : Preclinical and clinical data suggest safety and efficacy in attenuating elevated stress responseISING, Marcus; ZIMMERMANN, Ulrich S; KÜNZE, Heike E et al.Neuropsychopharmacology (New York, NY). 2007, Vol 32, Num 9, pp 1941-1949, issn 0893-133X, 9 p.Article

Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor₁ (CRF₁) receptorHOARE, Sam R. J; BROWN, Brock T; SANTOS, Mark A et al.Biochemical pharmacology. 2006, Vol 72, Num 2, pp 244-255, issn 0006-2952, 12 p.Article

Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonistsZHIQIANG GUO; TELLEW, John E; MCCARTHY, James R et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 16, pp 5104-5107, issn 0022-2623, 4 p.Article

Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine coreDYCK, Brian; GRIGORIADIS, Dimitri E; SCHWAEBE, Michael K et al.Journal of medicinal chemistry (Print). 2005, Vol 48, Num 12, pp 4100-4110, issn 0022-2623, 11 p.Article

Preterm birth : Associated neuroendocrine, medical, and behavioral risk factors : Hormones and reproductive healthERICKSON, Kristine; THORSEN, Poul; CHROUSOS, George et al.The Journal of clinical endocrinology and metabolism. 2001, Vol 86, Num 6, pp 2544-2552, issn 0021-972XArticle